# Expert Assessment: Closed-Loop tFUS Targeting PV Interneurons in AD
## Executive Summary
This hypothesis represents an ambitious integration of neuromodulation technology with molecular pathology targeting. While conceptually sophisticated, several translational barriers significantly reduce clinical probability of success. The mechanistic chain contains validated segments but critical gaps in cellular specificity and causal validation.
---
## 1. Target Druggability Assessment
### PVALB as Direct Target: **NOT TRADITIONALLY DRUGGABLE**
| Factor | Evaluation | Comments |
|--------|------------|----------|
| Gene product class | Calcium-binding protein | Structural protein, not enzyme/receptor with active site |
| Active site availability | Limited | Protein-protein interaction interface, no canonical binding pocket |
| Upstream pathway druggability | **MODERATE-HIGH** | Neuroactive compounds, genetic tools, neuromodulation |
| Downstream effectors | **EXPLORABLE** | AnkyrinG, VGSC trafficking, gamma oscillation machinery |
**Key Insight:** The hypothesis cleverly avoids needing a PVALB